Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes
Open accessThe DOI matches its Crossref record; 48 of the 48 references it cites were found in a registry or an index; 24 of the 34 sources its claims cite were checked for support.
Abstract
BACKGROUND: Semaglutide, a glucagon-like peptide-1 receptor agonist, has been shown to reduce the risk of adverse cardiovascular events in patients with diabetes. Whether semaglutide can reduce cardiovascular risk associated with overweight and obesity in the absence of diabetes is unknown. METHODS: In a multicenter, double-blind, randomized, placebo-controlled, event-driven superiority trial, we enrolled patients 45 years of age or older who had preexisting cardiovascular disease and a body-mass index (the weight in kilograms divided by the square of the height in meters) of 27 or greater but no history of diabetes. Patients were randomly assigned in a 1:1 ratio to receive once-weekly subcutaneous semaglutide at a dose of 2.4 mg or placebo. The primary cardiovascular end point was a composite of death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke in a time-to-first-event analysis. Safety was also assessed. RESULTS: A total of 17,604 patients were enrolled; 8803 were assigned to receive semaglutide and 8801 to receive placebo. The mean (±SD) duration of exposure to semaglutide or placebo was 34.2±13.7 months, and the mean duration of follow-up was 39.8±9.4 months. A primary cardiovascular end-point event occurred in 569 of the 8803 patients (6.5%) in the semaglutide group and in 701 of the 8801 patients (8.0%) in the placebo group (hazard ratio, 0.80; 95% confidence interval, 0.72 to 0.90; P<0.001). Adverse events leading to permanent discontinuation of the trial product occurred in 1461 patients (16.6%) in the semaglutide group and 718 patients (8.2%) in the placebo group (P<0.001). CONCLUSIONS: In patients with preexisting cardiovascular disease and overweight or obesity but without diabetes, weekly subcutaneous semaglutide at a dose of 2.4 mg was superior to placebo in reducing the incidence of death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke at a mean follow-up of 39.8 months. (Funded by Novo Nordisk; SELECT ClinicalTrials.gov number, NCT03574597.).
Overview
CoChat Summary
## TL;DR
In this multicenter randomized trial of adults with preexisting cardiovascular disease, overweight or obesity, and no diabetes, weekly semaglutide 2.4 mg reduced major cardiovascular events versus placebo over a mean 39.8 months. The benefit came with more adverse-event-related discontinuation, especially gastrointestinal events.
## Key findings
- The primary composite cardiovascular end point occurred in 569/8803 (6.5%) semaglutide patients vs 701/8801 (8.0%) placebo patients (hazard ratio 0.80; 95% CI, 0.72 to 0.90; P<0.001).
- Mean body weight change over 104 weeks was -9.39% with semaglutide vs -0.88% with placebo, an estimated treatment difference of -8.51 percentage points (95% CI, -8.75 to -8.27).
- Adverse events leading to permanent discontinuation occurred in 1461 (16.6%) semaglutide patients vs 718 (8.2%) placebo patients (P<0.001); gastrointestinal disorders accounted for 880 (10.0%) vs 172 (2.0%).
- The paper reports fewer serious adverse events with semaglutide: 2941 (33.4%) vs 3204 (36.4%) (P<0.001), while gallbladder-related disorders were slightly higher: 246 (2.8%) vs 203 (2.3%) (P=0.04).
## Methods
- Multicenter, double-blind, randomized, placebo-controlled, event-driven superiority trial at 804 clinical sites in 41 countries.
- Enrolled 17,604 patients aged 45 years or older with BMI ≥27, established cardiovascular disease, and no history of diabetes; randomized 1:1 to weekly subcutaneous semaglutide 2.4 mg or placebo.
- Primary analysis was intention-to-treat time-to-first-event analysis using a Cox proportional hazards model; secondary end points were tested hierarchically.
## Limitations
- The paper states that it included only patients with preexisting cardiovascular disease, so effects on primary prevention in people with overweight/obesity but no prior atherosclerotic disease were not studied.
- The authors note the patient population was not globally representative, with 27.7% women and 3.8% Black persons enrolled.
- Evident from the report: although mean follow-up was 39.8 months, the x-axis in the figure is truncated at 48 months because of limited patients after that time, so very long-term effects are not fully established.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
17 Valid · 0 Not valid · 5 Not checked · 53 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Perivascular and epicardial adipose tissue impose direct adverse effects on the vascular endothelium and myocardium. 30”
What the sources say
- Partly supportedcites [30] 30. Iacobellis G. Epicardial adipose tissue in contemporary cardiology. Nat Rev Cardiol 2022; 19: 593-606. sourceExperimental — accuracy not yet measured
The Introduction says epicardial adipose tissue (EAT) can harm adjacent myocardium through inflammatory and profibrotic secretions, and the Coronary artery disease section says EAT secretes factors associated with increased endothelial permeability. The paper identifies pericoronary EAT around coronary arteries, but does not establish the claim for perivascular adipose tissue generally. It also describes EAT as protective under normal conditions, so the unqualified assertion of adverse effects overstates the source. These sections have no page numbers in our copy. (LLM, conf=0.85)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Semaglutide, a long-acting analogue of GLP-1, administered at a dose of 2.4 mg subcutaneously once weekly for 104 weeks, was found to reduce body weight by a mean of 15.2% among patients with overweight or obesity who did not have diabetes. 18”
What the sources say
- Supportedcites [18] 18. Garvey WT, Batterham RL, Bhatta M, et al. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nat Med 2022; 28: 2083-91. 19. Ryan DH, Lingvay I, Colhoun HM, et al. Semaglutide effects on cardiovascular outcomes in people with overweight or obesity (SELECT) rationale and design. Am Heart J 2020; 229: 61-9. source
The Methods (Procedures; page not provided) describe once-weekly subcutaneous semaglutide 2.4 mg for 104 weeks in addition to behavioral intervention. The Discussion reports a mean 15.2% weight loss at week 104 in adults with overweight or obesity without diabetes. (LLM, conf=0.94)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“and the 37.8-percentage-point decrease in the high-sensitivity C-reactive protein level with semaglutide in this trial is similar to that reported with statins. 36”
What the sources say
- Supportedcites [36] 36. Asher J, Houston M. Statins and C-reactive protein levels. J Clin Hypertens (Greenwich) 2007; 9: 622-8. source
The “CRP Reductions With Statins” section reports CRP reductions of 29% and 43% with atorvastatin monotherapy, making the citing trial’s 37.8-percentage-point decrease a reasonable comparison. The source notes that reductions vary by statin and regimen; it does not assess semaglutide itself. (LLM, conf=0.92)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Similarly, bariatric surgery, in which reductions in body weight of more than 20% can be achieved, has been associated with fewer cardiovascular events than usual care. 33,34”
What the sources say
- Partly supportedcites [33] 33. Mentias A, Aminian A, Youssef D, et al. Long-term cardiovascular outcomes after bariatric surgery in the Medicare population. J Am Coll Cardiol 2022; 79: 1429-37. sourceExperimental — accuracy not yet measured
The Results report fewer heart-failure hospitalizations, myocardial infarctions, and ischemic strokes after bariatric surgery than in the matched control group; the Discussion describes that group as managed conservatively. The Discussion says surgery induces substantial, sustained weight loss, but our copy does not give the claimed reduction of more than 20% of body weight. (LLM, conf=0.88)
- Not checked — no full text of the sourcecites [34] 34. Sjöström L, Peltonen M, Jacobson P, et al. Bariatric surgery and long-term cardiovascular events. JAMA 2012; 307: 56-65. source
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“In addition, reductions in excess abnormal body fat ameliorate the systemic proinflammatory and prothrombotic milieu associated with obesity. 31”
What the sources say
- Partly supportedcites [31] 31. Magkos F, Fraterrigo G, Yoshino J, et al. Effects of moderate and subsequent progressive weight loss on metabolic function and adipose tissue biology in humans with obesity. Cell Metab 2016; 23: 591-601. sourceExperimental — accuracy not yet measured
The Results and Discussion (page unavailable) report that 11%–16% weight loss was associated with reduced systemic inflammation, but 5% weight loss did not reduce circulating inflammatory markers. The paper does not report an improvement in a prothrombotic milieu, so it supports only the inflammatory part of the claim and only at the greater weight-loss levels studied. (LLM, conf=0.88)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
37 more claims · 6 with their cited sources checked
Create a free account to see all 75 claims and every source verdict.
- Probably not a substantial claim. 27
- It may state two separate claims as one. 12
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“and, more recently, in people with obesity without diabetes [4].”
From Effects of GLP ‐1 Receptor Agonists and Dual GIP / GLP ‐1 Receptor Agonists on Inflammatory and Metabolic Biomarkers in Type 2 Diabetes: A Systematic Review and Meta‐Analysis (2026) · cites this paper as [4]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“People were able to maintain approximately 10% WL over a 4-year period, and the proportion of participants experiencing SAE during the trial was lower in those assigned to semaglutide 2.4 mg compared to placebo (33.4% vs. 36.4%).”
From What is the pipeline for future medications for obesity? (2025) · cites this paper as [110]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The SELECT trial is the first study providing long-term data on the safety and efficacy of semaglutide 2.4 mg [110].”
From What is the pipeline for future medications for obesity? (2025) · cites this paper as [110]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The SELECT trial demonstrated a 20% reduction in MACE among patients with obesity and established cardiovascular disease [15,85].”
From Adherence and Persistence with GLP-1-Based Therapies: International Real-World Evidence and the Role of Nutritional and Lifestyle Support—A Narrative Review (2026) · cites this paper as [15]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The findings of benefit on all cardiovascular outcomes and death due to any cause are consistent with the previous meta-analysis but are expanded in important ways including the demonstration of benefit in a population with chronic kidney disease, as well as people with overweight or obese and cardiovascular disease but without diabetes. 26,27”
From Effects of GLP-1 receptor agonists on kidney and cardiovascular disease outcomes: a meta-analysis of randomised controlled trials (2025) · cites this paper as [27]
Experimental — accuracy not yet measured
71 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Health effects of overweight and obesity in 195 countries over 25 years
Collaborators, T. G. 2. O. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1614362 · Cited by 7,918
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603827 · Cited by 7,629
Self-citationSemaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Marso, S. P., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, L. A., Lingvay, I., Rosenstock, J., Seufert, J., Warren, M. L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607141 · Cited by 6,900
Self-citationCholesterol Treatment Trialists' (CTT) Collaboration (2010) · The Lancet · doi:10.1016/s0140-6736(10)61350-5 · Cited by 6,550
A Randomized Trial of Intensive versus Standard Blood-Pressure Control
The SPRINT Research Group (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1511939 · Cited by 6,325
Hubert, H. B., Feinleib, M., McNamara, P. M., & Castelli, W. P. (1983) · Circulation · doi:10.1161/01.cir.67.5.968 · Cited by 4,241
Drucker, D. J., & Nauck, M. A. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69705-5 · Cited by 3,896
Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes
The Look AHEAD Research Group (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1212914 · Cited by 2,908
Statistical Models Based on Counting Processes
Andersen, P. K., Borgan, Ø., Gill, R. D., & Keiding, N. (1993) · Springer Series in Statistics · doi:10.1007/978-1-4612-4348-9 · Cited by 2,855
Cited by
Items 1,401–1,500 of 3,116
Ferreira, J. P., Taveira‐Gomes, T., Lopes, R., Seabra, D., Bernardo, F., & Gavina, C. (2025) · BMJ Open · doi:10.1136/bmjopen-2024-094853 · Cited by 5
“It should also be highlighted that because albuminuria was not available in most patients classified as having CKD, we could not use KDIGO classification for kidney disease.”
Do weight loss interventions challenge the obesity paradox in heart failure?
Yurista, S. R., Eder, R. A., Butsch, W. S., & Luptak, I. (2025) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2025.01.006 · Cited by 5
Dennis, C. J., He, A. Z., Krishnaraj, A., Quan, A., Teoh, H., Connelly, K. A., Hess, D. A., & Verma, S. (2026) · Circulation Research · doi:10.1161/circresaha.126.327425 · Cited by 4
Novel antidiabetic therapies in patients with peripheral artery disease: current perspective
Janić, M., Maggio, V., Janež, A., & Rizzo, M. (2024) · Frontiers in Clinical Diabetes and Healthcare · doi:10.3389/fcdhc.2024.1517265 · Cited by 3
Diallo, A., Carlos‐Bolumbu, M., Duc, P., & Galtier, F. (2025) · EClinicalMedicine · doi:10.1016/j.eclinm.2025.103506 · Cited by 4
Racial and demographic disparities in glp-1ra use among breast cancer patients with Type 2 Diabetes
Hundal, J., Ashruf, O. S., Li, H., Basen‐Engquist, K., Kaelber, D. C., & Sukumar, J. S. (2025) · npj Breast Cancer · doi:10.1038/s41523-025-00844-6 · Cited by 6
Promising results but caution needed in GLP-1RA large scale epidemiology
Deo, S. V., & Sattar, N. A. (2025) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2025.03.015 · Cited by 3
What is new in cardiac anesthesia in 2024?
Tang, Z., Lin, A., Liu, H., & Zhao, M. (2025) · Journal of Anesthesia and Translational Medicine · doi:10.1016/j.jatmed.2025.03.001 · Cited by 6
Feghali, J., Ruchika, F., Horowitz, M. A., Xu, R., Jackson, C. M., Caplan, J. M., Huang, J., Tamargo, R. J., & Gonzalez, L. F. (2026) · Stroke · doi:10.1161/strokeaha.125.053599 · Cited by 3
An Evaluation of Primary Care Clinician Referrals for Behavioral Weight Loss Counseling
Saraiya, V., Berkowitz, S. A., Johnston, L. F., Couper, D. J., Sotres‐Alvarez, D., Lyons, K. M., Thaxton, C. K., Skinner, H. G., Samuel‐Hodge, C. D., & Keyserling, T. C. (2024) · Journal of Primary Care & Community Health · doi:10.1177/21501319241308054 · Cited by 3
Reframing the Role of Glucagon-Like Peptide 1 Receptor Agonists in Cardiovascular Medicine
Inciardi, R. M., Chandra, A., Pandey, A., & Metra, M. (2024) · ESC Heart Failure · doi:10.1002/ehf2.15123 · Cited by 4
Avogaro, A., Neccia, M., Delfini, M., Franculli, A., Enea, G., Magli, A., Bemporad, J. A., & Fadini, G. P. (2026) · Acta Diabetologica · doi:10.1007/s00592-026-02666-9 · Cited by 4
Villelabeitia, I. K., COHEN, R. V., & le Roux, C. W. (2026) · Heart · doi:10.1136/heartjnl-2025-326812 · Cited by 4
“29 Durability with GLP-1 RAs across trials shows that benefits are largely maintained on-treatment, and major weight regain occurs after withdrawal over 2 years, supporting the view that obesity pharmacotherapy requires chronic use, 15 16 47 refer to table 5.”
The Cardiovascular Benefits of Glucagon-like Peptide-1 (GLP-1) Receptor Agonists
Kallash, M., & Frishman, W. H. (2025) · Cardiology in Review · doi:10.1097/crd.0000000000000970 · Cited by 4
Seeking and treating inflammation in ischaemic heart disease: are we ready?
Prati, F., Mastroianni, F., Paoletti, G., Marco, V., Biccirè, F. G., & Gatto, L. (2025) · European Heart Journal Supplements · doi:10.1093/eurheartjsupp/suaf029 · Cited by 3
Samanidou, V., Tsamis, K., Ceasovschih, A., Koufakis, T., Patoulias, D., Rizos, E. C., Rizzo, M., Milionis, H. J., & Barkas, F. (2026) · Journal of Central Nervous System Disease · doi:10.1177/11795735261444425 · Cited by 4
“6,33,35,36 Importantly, these CVOT data primarily inform long-term cerebrovascular prevention, given their design, follow-up duration, and population characteristics, rather than acute stroke biology or early neurological recovery.”
Samuel, A. H., Kshatri, A. H. S., Babu, R. N., Patel, H. S., Viswanathan, S. H., Challa, M. S. R., & Swathi, N. L. (2026) · Annales d Endocrinologie · doi:10.1016/j.ando.2026.102494 · Cited by 4
Hunter, T. M., Hankosky, E. R., Meeks, A., Liao, B., Ward, J., Huang, A., & Chinthammit, C. (2025) · Clinical Therapeutics · doi:10.1016/j.clinthera.2025.05.003 · Cited by 3
Zhang, L., Kulkarni, P., Farshidfar, F., Tingley, W. G., Hoey, T., Wang, W., Priest, J. R., & Figarska, S. M. (2025) · BMC Cardiovascular Disorders · doi:10.1186/s12872-025-04753-1 · Cited by 3
Mendes, T. B., Generoso, G., Fabiano, R. C., Halpern, B., Janovsky, C. C. P. S., Romero, C. M., Santos, R. D., Benseñor, I. M., Lotufo, P. A., & Bittencourt, M. S. (2025) · The Lancet Regional Health - Americas · doi:10.1016/j.lana.2025.101281 · Cited by 5
Vignarajah, A., Tan, M. C., Winson, T., et al. (2025) · JACC. Clinical electrophysiology · doi:10.1016/j.jacep.2025.09.038 · Cited by 2
Ferrera, A., Gallo, G., & Volpe, M. (2024) · High Blood Pressure & Cardiovascular Prevention · doi:10.1007/s40292-024-00626-4 · Cited by 2
Vettor, R., Petroni, M. L., Dotan, I., Lalazar, G., Haluzík, M., Spearman, C. W., Dave, J. A., Abaalkhail, F. A., Abusnana, S., Alshehri, A. A., et al. (2026) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-026-10027-8 · Cited by 6
“In terms of multi-system benefits, semaglutide reduced major adverse cardiovascular events (MACE) by 20% in adults with CVD and overweight/obesity and by 26% in people with CVD and T2D [113, 114].”
Vecchiato, M., Palermi, S., Zámodics, M., Babity, M., Eftekhari, M., Ryali, R., Luk, J., Taseh, A., Ashkani‐Esfahani, S., Merkely, G., et al. (2026) · Sports Medicine - Open · doi:10.1186/s40798-026-01026-9 · Cited by 5
“These cardioprotective effects appear mediated by weight reduction, improved endothelial function, and anti-inflammatory actions [108–111].”
Use of Glucagon-Like Peptide-1 Receptor Agonists in Patients with Left Ventricular Assist Devices
Ibrahim, R., Pham, H. N., Abdelnabi, M. H., Forst, B. J., Allam, M., Mee, X. C., Lim, G. K., Bcharah, G., Barry, T., Farina, J., et al. (2025) · ESC Heart Failure · doi:10.1002/ehf2.15379 · Cited by 3
Frey, S., Louis-Gaubert, C., Thouzeau, A., Cossé, L., Lorant, V., Prieur, X., Flet, L., Cariou, B., Blanchard, C. L., & May, C. L. (2025) · Obesity · doi:10.1002/oby.70003 · Cited by 2
An anti-PCSK9 pill a day to keep cholesterol away: next steps?
Watts, G. F. (2024) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(23)00358-3 · Cited by 3
Hurwitz, S. R., Lanes, S., Quimbo, T., Papazian, A., White, J., Fisher, V. L., Cziraky, M. J., Crowley, M. J., & Willey, V. J. (2025) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.70214 · Cited by 7
Tirzepatide for Weight Reduction in Chinese Adults With Obesity—Reply
Zhao, L., & Li, X. (2024) · JAMA · doi:10.1001/jama.2024.21783 · Cited by 2
U.S. Emergency Department Visits Attributed by Clinicians to Semaglutide Adverse Events, 2022–2023
Lovegrove, M. C., Stone, N. D., Geller, A. I., Weidle, N. J., Lind, J. N., & Cohen, P. A. (2025) · Annals of Internal Medicine · doi:10.7326/annals-24-03258 · Cited by 4
Characterization of Interchanging Incretin Analogs in Clinical Practice: A Descriptive Report
Hvisdas, C., Goode, N., Kim, D. H., Silvey, M. J., & Flood, J. J. (2024) · Endocrine Practice · doi:10.1016/j.eprac.2024.09.117 · Cited by 2
Ding, Q., Sico, J. J., Perkins, A. J., Myers, L. J., Daggy, J., Sexson, A. E., Taylor, S., Burrone, L., Waddell, K. J., & Bravata, D. M. (2026) · Cardiovascular Diabetology – Endocrinology Reports · doi:10.1186/s40842-026-00280-w · Cited by 2
Pradhan, A. K., Prajapati, S., & Vishwakarma, P. (2024) · Heart India · doi:10.4103/heartindia.heartindia_20_24 · Cited by 2
Fei, S., Yang, A., Jin, Y., Tian, L., Yu, X., Liang, S., Zhang, W., Zhao, G., & Gao, B. (2025) · Postgraduate Medicine · doi:10.1080/00325481.2025.2570106 · Cited by 2
“%) reduction in the SURMOUNT-1 trial [45,46], However, these therapies may also reduce muscle mass during weight loss: semaglutide was associated with a 6.92 kg (13.2”
InfluentialSemaglutide in patients with hidradenitis suppurativa and obesity
Nicolau, J., Sanchís, P., Nadal, A., Tamayo, M. I., Sfondrini, G., Oliver, M. G., García, P., Nadal, C., & Masmiquel, L. (2026) · Medicina Clínica (English Edition) · doi:10.1016/j.medcli.2026.107405 · Cited by 5
Exocrine Pancreatic Insufficiency During the Use of Semaglutide: A Case Report
de Melo, C. A., Júnior, N. E. G., Ribeiro-Sousa, M. A. D. S., & da Cunha, S. F. D. C. (2024) · Cureus · doi:10.7759/cureus.55549 · Cited by 2
Bruun, K., & Mortensen, M. B. (2024) · Current Opinion in Cardiology · doi:10.1097/hco.0000000000001188 · Cited by 2
Facciorusso, A., Giannini, E. G., Tacelli, M., Zanetto, A., Spada, C., Boskoski, I., Furnari, M., Pennisi, G., Capurso, G., Vitello, A., et al. (2026) · Digestive and Liver Disease · doi:10.1016/j.dld.2026.02.018 · Cited by 3
Barenbaum, S. R., Aras, M., Kashyap, S. R., & Aronne, L. J. (2025) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaf641 · Cited by 2
Sandsdal, R. M., Holt, J., Alkhefagie, H. G. A., Jørgensen, J. R., Juhl, C. R., Olsen, L. M., Byberg, S., Thirumathyam, R., Gliemann, L., Stallknecht, B. M., et al. (2026) · Nature Metabolism · doi:10.1038/s42255-026-01554-4 · Cited by 3
“Both exercise and glucagon-like peptide-1 receptor agonists (GLP-1 RAs) individually seem to promote cardiovascular health 7–10 .”
Færch, K., Gomes, M., Bramming, M., Sørensen, M. R., & Strathe, A. (2026) · Advances in Therapy · doi:10.1007/s12325-026-03507-5 · Cited by 2
“This underscores a need for effective treatment options, e.g. medications such as semaglutide 2.4 mg, which can reduce weight as well as risk of comorbidities [3].”
InfluentialKhunti, K., Mourer, A., Capucci, S., Wilkinson, L., Andersen, K. K., Tahrani, A. A., & Morgen, C. S. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70446 · Cited by 6
“25,34 The relationship between weight loss and mental health is of particular interest.”
The GLP-1 RA boom: Trends in publicly subsidised and private access in Australia, 2020-2025Preprint
Falster, M. O., Costa, J. D. O., Milder, T. Y., Carson, J. M., Shadbolt, C., Neuen, B. L., Arnott, C. G., Wilson, A. J., Jun, M., Pratt, N. L., et al. (2025) · medRxiv · doi:10.1101/2025.10.30.25339120 · Cited by 2
Fernández-Ruíz, I. (2023) · Nature Reviews Cardiology · doi:10.1038/s41569-023-00970-3 · Cited by 2
Pharmacotherapy of obesity: State of the art and perspectives
Sićović, K., & Micov, A. M. (2024) · Arhiv za farmaciju · doi:10.5937/arhfarm74-50625 · Cited by 3
More than a sidekick: GIP signalling and cardiovascular outcomes
Kurt, B., & Kahles, F. (2025) · European Heart Journal · doi:10.1093/eurheartj/ehaf944 · Cited by 3
“8,14 Additional CVOTs addressing the twincretin axis (GLP-1 and GIP) in patients with obesity and ASCVD are ongoing (SURMOUNT-MMO, NCT05556512; MARITIME-CV, NCT07037433).”
InfluentialGLP-1 RAs: The newest powerhouse in metabolic medicine
Drake, E. S., Marino, A. B., Theroux, J. D., & Roberts, K. (2024) · The Nurse Practitioner · doi:10.1097/01.npr.0000000000000216 · Cited by 2
Khan, S., Herbst, W., Tajrishi, F. Z., Notani, S., Knight, A., Jamil, Z., & Ferdinand, K. C. (2026) · Biomedicines · doi:10.3390/biomedicines14040743 · Cited by 4
“For instance, in the landmark SELECT trial, semaglu-tide was superior to placebo in reducing a composite of death from cardiovascular causes and non-fatal or non-fatal stroke [85,87].”
Wu, J., Lee, K.-W., Huang, S.-C., Chang, H.-Y., & Lin, Y. (2026) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2026.113273 · Cited by 2
King, A. C., Wellendorf, C. E., Atkinson, E. A., de Carvalho, M. E. A., Fridberg, D. J., & Pannain, S. (2025) · Journal of Addiction Medicine · doi:10.1097/adm.0000000000001565 · Cited by 2
Issachar, A., Razi, T., Borochov, I., Duskin‐Bitan, H., & Arbel, R. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70763 · Cited by 4
“In addition to their metabolic effects, GLP-1RAs are associated with decreased cardiovascular risk even in patients without T2DM [10].”
Lai, S., Feng, Y., Li, L., Zhao, J., Wang, Z., & Wang, Y. (2025) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-025-01866-7 · Cited by 2
Fawsitt, C. G., Thom, H. H. Z., Aceituno, D., Jarde, A., Larsen, S., Lübker, C., Kayongo, E., Keeney, E., & FOOS, V. (2025) · PharmacoEconomics · doi:10.1007/s40273-025-01555-3 · Cited by 2
“The independent validation of CV and mortality outcomes in the normoglycaemia/prediabetes population ( N = 58), based on five different sources [20, 22–25], resulted in a generally high R 2 (0.90) with some under-prediction (OLS LRL = 0.86) [Table 1; Fig.”
InfluentialNielsen, C. K., Pálsson, T. G., Forman, J. L., Lukacova, M., Jensen, B. A., Mathiesen, D. S., Englund, A., Gether, I. M., Johansen, N. J., Pedersen, M. G., et al. (2026) · EClinicalMedicine · doi:10.1016/j.eclinm.2026.103801 · Cited by 3
“14 Nevertheless, besides treat-ment durability, receptor desensitisation, or long-term tolerability, 15 challenges still remain, particularly concerning targeting obesity-associated systemic inflammation characterised by increased circulating levels of acute phase proteins and inflammatory…”
Current clinical application of incretin therapy for obesity management
Skinner, K., & Clements, J. N. (2025) · Canadian Journal of Physiology and Pharmacology · doi:10.1139/cjpp-2025-0152 · Cited by 5
Chen, Y., Fang, C., Zhao, J., Jiang, S., Xu, X., Cui, L., Zhao, R., Ma, X., Lin, T., Yu, H., et al. (2025) · European Heart Journal - Cardiovascular Imaging · doi:10.1093/ehjci/jeaf219 · Cited by 2
EndoBridge 2024: pearls and highlights
Yıldız, B. O., Armeni, E., Balodimou, C., Biondi, B., Ciudin, A., Frühbeck, G., Fuleihan, G. E., Geer, E. B., Gillard, P., Gordon, C. M., et al. (2025) · HORMONES · doi:10.1007/s42000-025-00708-5 · Cited by 4
Fountoulakis, N., Pavlou, P., Stathi, D., Goubar, A., Corcillo, A., Flaquer, M., Ayis, S. A., Gnudi, L., & Karalliedde, J. J. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70481 · Cited by 3
“CVOT in people with T2D and people with obesity without T2D demonstrated reduced risk of CVD events and CVD mortality in those treated with semaglutide as compared to placebo [8,38].”
Horn, D. B., Aronne, L. J., Wharton, S., Bays, H. E., Valderas, E. G., Arad, A. D., Sharma, P., Dunn, J. P., Şenyücel, Ç., & Lee, C. J. (2025) · Obesity · doi:10.1002/oby.70014 · Cited by 3
Are the lipid-lowering effects of incretin-based therapies relevant for cardiovascular benefit?
Alnima, T., Smits, M. M., & Hanssen, N. M. J. (2024) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000949 · Cited by 3
Loh, W. J. (2024) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000892 · Cited by 4
Levi, O., Dalal, N., Komissar, A., Moldavsky, D., Khamaisi, S., Elyagon, S., Murninkas, M., Eliyahu, A., Burg, S., Attali, B., et al. (2026) · EP Europace · doi:10.1093/europace/euag091 · Cited by 3
“31,32 GLP-1 RAs may act on the cardiovascular system through multiple mechanisms, including enhanced endothelium-dependent vasodilation, reduced low-density lipoprotein (LDL) oxidation, and decreased lipid deposition in atherosclerotic plaques.”
Harrington, J. (2024) · Heart Failure Reviews · doi:10.1007/s10741-024-10408-8 · Cited by 2
What is the Role of Primary Prevention of Obesity in an Age of Effective Pharmaceuticals?
Gómez‐Martín, M., Canfell, O. J., Chai, L. K., Jansson, A. K., Littlewood, R., Sullivan, C. M., Power, D. D., Clarke, E. D., Ells, L. J., de Vlieger, N., et al. (2025) · Current Obesity Reports · doi:10.1007/s13679-025-00632-0 · Cited by 4
The past and future of obesity research
Blüher, M. (2025) · Nature Reviews Endocrinology · doi:10.1038/s41574-025-01172-2 · Cited by 4
Levin, A., Bansal, N., de Boer, I. H., Grams, M. E., Jadoul, M., ter Maaten, J. M., Mustafa, R. A., Rossing, P. R., Cheung, M., King, J. M., et al. (2026) · Kidney International · doi:10.1016/j.kint.2026.03.031 · Cited by 5
GLP-1RA Liraglutide Attenuates Sepsis by Modulating Gut Microbiota and Associated Metabolites
Gong, B., Shi, Z., Qi, J., Wang, F., Chen, G., & Su, H. (2026) · Nutrients · doi:10.3390/nu18030531 · Cited by 3
“Our findings suggest that liraglutide not only alters microbial composition but also functionally reprograms the microbial metabolic output, which has been a pivotal player in modulating host immune responses and systemic inflammation during critical illness [34,35].”
Zhong, M., Wu, X., Liu, Y., Mao, Y., Liu, M., Liu, X., & Liu, Q. (2026) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-026-07882-7 · Cited by 5
Jarvis, H., Brennan, P., Casanovas, T., Casler, K., Desai, M., Evans, P. H., Dillon, J. F., Grattagliano, I., Hallsworth, K., Hebditch, V., et al. (2026) · The Lancet. Gastroenterology & hepatology · doi:10.1016/s2468-1253(26)00015-4 · Cited by 5
Albon, E., Afentou, N., Dretzke, J., Hall, J., Ogwulu, C. O., Price, M. J., Clare, K., Singhal, R., Tahrani, A. A., Frew, E. J., et al. (2025) · Health Technology Assessment · doi:10.3310/pwkq2310 · Cited by 2
Dons, M., Näslund‐Koch, C., Sengeløv, M., Bøgh‐Sørensen, S., Skaarup, K. G., Løvendorf, M. B., Davidovski, F. S., Jensen, A. M. R., Weber, B., Gluud, L. L., et al. (2025) · Journal of Internal Medicine · doi:10.1111/joim.70053 · Cited by 3
“Therapies such as glucagon-like peptide-1 (GLP-1) receptor agonists have shown promise in reducing hepatic steatosis [41] and lowering CV risk among individuals with established CVD and elevated BMI [42].”
Kishimori, T., Kato, T., Wada, A., Tani, A., Yamaji, R., Koike, J., Iwasaki, Y., Μatsumoto, T., Yagi, T., & Okada, M. (2025) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2025-005364 · Cited by 5
“Additional prospective observational studies and randomized controlled trials are required to validate these findings.”
Nair, P. (2024) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2416868121 · Cited by 2
Cardiovascular-Related Maternal Mortality
Levine, L. D., Klammer, C., & Lewey, J. (2026) · Obstetrics and Gynecology · doi:10.1097/aog.0000000000006297 · Cited by 3
Orforglipron, an Oral GLP-1 Receptor Agonist, in Early Type 2 Diabetes
(2025) · New England Journal of Medicine · doi:10.1056/nejmc2515117 · Cited by 2
Gopalakrishnan, U. A., Joshi, A. S., Giri, R., Shah, S. J., Shukla, J., Maheshwari, S., Chowdaiah, R. M., Singh, M. K., Bari, A. S., Pathak, N. P., et al. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70891 · Cited by 3
“Large outcome trials have demonstrated that semaglutide confers benefits beyond glycaemic control in selected high-risk populations, including reductions in cardiovascular events and kidney disease progression [12, 33–36].”
Disse, E., Aron‐Wisnewsky, J., Jacobi, D., Clément, K., Laville, M., Gauthier, C., Pattou, F. N., Molleville, J., Akerib, M., Jubin, L., et al. (2025) · Diabetes & Metabolism · doi:10.1016/j.diabet.2025.101625 · Cited by 3
Incretins for management of obesity and obstructive sleep apnea
Hu, X., Yee, B. J., Phillips, C. L., Chapman, J. L., & Grunstein, R. R. (2025) · Expert Review of Respiratory Medicine · doi:10.1080/17476348.2025.2513516 · Cited by 2
Pharmacologic approach to metabolic dysfunction and related diseases: focus on liver aspects
Piazzolla, V., Napolitano, A., & Mangia, A. (2025) · Metabolism and Target Organ Damage · doi:10.20517/mtod.2025.152 · Cited by 2
Cardiovascular Risk Reduction With GLP-1 RA Drugs
Pigeyre, M., & Gerstein, H. C. (2026) · Circulation · doi:10.1161/circulationaha.126.079319 · Cited by 4
Armentaro, G., Vitale, C., Cassano, V., Panza, M., Gareri, I., Mirabelli, M., Succurro, E., Andreozzi, F., Brunetti, A., Savarese, G., et al. (2026) · Internal and Emergency Medicine · doi:10.1007/s11739-026-04499-4 · Cited by 2
Do, D., Murugiah, K., Sawano, M., et al. (2026) · JACC Advances · doi:10.1016/j.jacadv.2025.102575 · Cited by 2
Acute Pancreatitis Associated With Semaglutide in a Patient With Multimorbidity: A Case Report
Lo, S. C., & Yeh, H. (2026) · Cureus · doi:10.7759/cureus.101908 · Cited by 4
Burns, R. B., Jay, M. R., Thorndike, A. N., & Kanjee, Z. (2024) · Annals of Internal Medicine · doi:10.7326/annals-24-01740 · Cited by 2
“…of organs affected and modes of action may explain the extent of bene fi ts found beyond management of obesity, including treatment of metabolic dysfunction – associated stea-totic liver disease (MASLD; formerly called nonalcoholic fatty liver disease) and improvement in cardiovascular outcomes (5).”
Alfaris, N., Kushner, R. F., Li, J., Chen, K. L., Fenimore, M., Calderón, B., & Stefański, A. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70991 · Cited by 3
“The SELECT trial, powered to detect risk reduction of a composite of death from cardiovascular causes, nonfatal myocardial infarction or nonfatal stroke, found similar effects across multiple age subgroups in adults with obesity and without T2D treated with 2.4 mg semaglutide [40].”
InfluentialSelf-citationDăniluc, L., Braha, A., Sandu, O. E., Bogdan, C., Suhov, L., Ali, L. H., Lazăr-Höcher, A.-I., Sima, A. C., Apostol, A., & Ivan, V. M. (2025) · Medicina · doi:10.3390/medicina61040567 · Cited by 2
Guo, L., Ding, S., Wang, W., Zhang, H., Dai, S., Li, C., Yuan, Y., Stefański, A., Jouravskaya, I., & FORRESTER, T. D. (2025) · EClinicalMedicine · doi:10.1016/j.eclinm.2025.103722 · Cited by 5
Yang, Z., Li, Z., Gao, Y., Gao, A., Li, X., Wang, Y., Dou, K., Wang, X., Guo, T., & Qiu, H. (2026) · Journal of Inflammation Research · doi:10.2147/jir.s544921 · Cited by 2
“39,40 GLP-1 RAs exert their effects through dual central and peripheral mechanisms: centrally, they modulate brain regions controlling appetite to regulate hunger and energy expenditure via neurotransmitter and peptide release, while peripherally, they improve glycemic control by enhancing insulin…”
IDRIS, I. R. (2023) · Diabetes Obesity and Metabolism Now · doi:10.1002/doi2.82 · Cited by 2
Tsironikos, G. I., Tsolaki, V., Zakynthinos, G. Ε., Kyprianidou, D., Rammou, V., Antonogiannis, T., Mprotsis, T., Zakynthinos, Ε., & Bargiota, Α. (2025) · Frontiers in Clinical Diabetes and Healthcare · doi:10.3389/fcdhc.2025.1694808 · Cited by 3
“The effectiveness of semaglutide at lower doses, liraglutide in men, and SGLT2 inhibitors in patients without CVD and the potential synergistic effect of GLP-1 RAs and SGLT2 inhibitors need further evaluation.”
InfluentialDo glucagon-like peptide-1 based therapies alter the risk of late-onset inflammatory bowel disease?
Christensen, H. S., Andersen, D. V., Jess, T., & Allin, K. H. (2024) · Digestive and Liver Disease · doi:10.1016/j.dld.2024.01.183 · Cited by 2
Anti-Inflammatory Effects of Glucagon-Like Peptide-1 Receptor Agonists via the Neuroimmune Axis
Fang, S., & Wong, C. K. (2024) · DNA and Cell Biology · doi:10.1089/dna.2024.0057 · Cited by 3
Semaglutide: UK regulator approves drug for prevention of cardiovascular events
Iacobucci, G. (2024) · BMJ · doi:10.1136/bmj.q1660 · Cited by 2
Malik, A. P., & Malik, U. F. (2025) · International Journal of Cardiology · doi:10.1016/j.ijcard.2025.133237 · Cited by 2
L’hostellier, A., Kouanfack, C., Chazallon, C., Cardoso, S. W., Eholié, S. P., Banze, N., Halue, G., Capeau, J., Delaugerre, C., Moh, R., et al. (2026) · BMJ Open · doi:10.1136/bmjopen-2025-110560 · Cited by 2
GLP-1 Receptor Agonists for CKD: Remaining Issues or Mission Complete?
Kosjerina, V., & Rossing, P. R. (2025) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2025.03.001 · Cited by 2
Sardà, H., Genua, I., & Miñambres, I. (2025) · Medicina Clínica (English Edition) · doi:10.1016/j.medcle.2025.106951 · Cited by 3
Should Incretin Agonist-Based Drugs be Considered for First Line Antihypertensive Therapy?
Kylies, D., Dreher, L., & Wenzel, U. O. (2026) · Current Hypertension Reports · doi:10.1007/s11906-026-01374-7 · Cited by 2
Trott, M., Arnautovska, U., Johnston, D. J. G., Ritchie, G., & Siskind, D. J. (2026) · BJPsych Open · doi:10.1192/bjo.2026.12001 · Cited by 3
“In all three included trials, semaglutide yielded clinically meaningful improvements in weight and glycaemic outcomes, with high certainty evidence for reductions in body mass index, body weight and haemoglobin A1c, and moderate certainty for fasting glucose, compared with placebo.”
Airosus, C., Ardabili, N. G., Hyde, A., & Davidson, T. L. (2025) · Physiology & Behavior · doi:10.1016/j.physbeh.2025.114955 · Cited by 2
Metadata
- Authors
- Lincoff, A. M., Brown-Frandsen, K., Colhoun, H. M., Deanfield, J., Emerson, S. S., Esbjerg, S., Hardt-Lindberg, S., Hovingh, G. K., Kahn, S. E., Kushner, R. F., Lingvay, I., Oral, T. K., Michelsen, M. M., Plutzky, J., Tornøe, C. W., & Ryan, D. H.
- Affiliations
- Cleveland Clinic (US)
- From the Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland (A.M.L.); Novo Nordisk, Søborg, Denmark (K.B.-F., S.E., S.H.-L., G.K.H., T.K.O., M.M.M., C.W.T.); the Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh (H.M.C.), and the National Institute for Cardiovascular Outcomes Research, University College London, London (J.D.) — both in the United Kingdom; the Department of Biostatistics, University of Washington (S.S.E.), and the Department of Medicine, VA Puget Sound Health Care System and University of Washington (S.E.K.) — both in Seattle; the Department of Vascular Medicine, Academic Medical Center, Amsterdam (G.K.H.); the Department of Medicine, Feinberg School of Medicine, Northwestern University, Chicago (R.F.K.); the Department of Internal Medicine (Endocrinology Division) and Peter O’Donnell Jr. School of Public Health, University of Texas Southwestern Medical Center, Dall...
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2023-12-14
- Volume
- 389
- Issue
- 24
- Pages
- 2221-2232
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W4388592674
- Cited by
- 3,236
- References
- 42
- Citations by year
- 2026: 1298 · 2025: 1114 · 2024: 796 · 2023: 25
- FWCI
- 658.51
- Type
- journal article
- Language
- en
- Open access
- green
- discovery.ucl.ac.uk
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- UCL Discovery (University College London) (submittedVersion)
- Nova Science Publishers (Nova Science Publishers, Inc.) (submittedVersion)
- Dspace Repository (Marmara Üniversitesi) (submittedVersion)
- Pure Amsterdam UMC (submittedVersion, other-oa)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion, other-oa)
- Funders
- Novo Nordisk Pharma
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- semaglutide, obesity, overweight, cardiovascular outcomes, GLP-1 receptor agonists, pre-existing cardiovascular disease, myocardial infarction, stroke, cardiovascular mortality, adverse events, body mass index, weight loss, SGLT2 inhibitors, SELECT trial, drug safety and efficacy, non-diabetic patients, drug discontinuation, time to first event
- MeSH terms
- Glucagon-Like Peptide-1 Receptor Agonists, Semaglutide, Cardiovascular Agents, Cardiovascular Diseases, Diabetes Mellitus, Type 2, Double-Blind Method, Glucagon-Like Peptides, Humans, Hypoglycemic Agents, Myocardial Infarction, Obesity, Stroke, Overweight
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-09-28, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-09-28 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
